Resection of pulmonary metastases following chemotherapy for high stage testicular tumors


Eskicorapci S., Ekici S., Atsu M., Dogan R., Ozen H.

International Journal of Urology, cilt.11, sa.8, ss.634-639, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 8
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1111/j.1442-2042.2004.00869.x
  • Dergi Adı: International Journal of Urology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.634-639
  • Anahtar Kelimeler: germ cell tumor, postchemotherapy resection, surgery, testicular tumor, thoracic mass, GERM-CELL TUMORS, POSTCHEMOTHERAPY RESIDUAL MASSES, RETROPERITONEAL MASSES, CANCER, TERATOMA, TESTIS, MANAGEMENT, THERAPY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Our objective was to analyze retrospectively our experience with 19 patients who had metastatic germ cell testicular tumor and had undergone resection of pulmonary metastases following chemotherapy. We wished to determine the necessity of thoracic surgery on these patients. Methods: Of 103 patients in need of postchemotherapeutic surgery for metastatic germ cell testicular tumors, 19 patients (mean age 31) underwent surgery for thoracic masses following cis-platin based chemotherapy. Resection of pulmonary metastases was performed on patients with normal tumor markers after chemotherapy, who did not achieve complete radiological remission. Histopathological findings, correlation with the pathology of abdominal surgery and probable prognostic factors for disease-free and overall survivals were evaluated. Results: Disease-free and overall survival rates were 14/19 (73%) and 16/19 (84%), respectively, within a median follow-up time of 30 months (15-212 months). Patients with and without viable tumor cells in their thoracic histopathological specimen had 40% and 85% disease-free survival rates, respectively (P < 0.05). Eight patients had both abdominal and thoracic postchemotherapy surgery. Only two (25%) of these patients had the same histopathological features at both sites. Conclusions: All patients with residual thoracic masses must be considered candidates for surgery, because there are no predictive factors to determine the thoracic pathology without surgery. With the resection of the pulmonary metastases only, surgery can be performed without significant morbidity and is essential to select patients for further chemotherapy, to remove all visible masses and to provide histopathological confirmation. Patients with viable tumor cells in the thoracic surgical specimen have a poor prognosis.